Reuters logo
5 months ago
BRIEF-Novo Nordisk files for regulatory approval of once-weekly semaglutide in Japan
February 28, 2017 / 6:19 AM / 5 months ago

BRIEF-Novo Nordisk files for regulatory approval of once-weekly semaglutide in Japan

1 Min Read

Feb 28 (Reuters) - Novo Nordisk A/S

* Novo Nordisk on Tuesday announced the submission of a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare for semaglutide, a new glucagon-like peptide-1 (GLP-1) analogue administrated once-weekly, for the treatment of adults with type 2 diabetes Source text for Eikon: Further company coverage: (Reporting by Jacob Gronholt-Pedersen)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below